Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical data demonstrating enhanced systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1).  IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera.  IDO is one of several immune checkpoints involved in tumor immune escape. IDO-1 inhibitors are currently in clinical development.  These data are being presented at the AACR Annual Meeting 2016 in New Orleans, LA.

“There is an extensive body of evidence which demonstrates that modulating the tumor microenvironment is critical to a successful outcome in cancer immunotherapy”, statedSudhir Agrawal, D.Phil., President of Research at Idera Pharmaceuticals.  “In preclinical models, previously we have seen compelling systemic anti-tumor effects with intra-tumoral IMO-2125 monotherapy, in combination with inhibitors of CTLA-4, PD-1, and now, IDO.”

In the presentation, entitled “Creating the tumor microenvironment for effective immunotherapy:  Anti-tumor activity of intra-tumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO),”  Idera scientists presented data further supporting the hypothesis that intra-tumoral IMO-2125 changes the tumor microenvironment by increasing tumor-infiltrating lymphocytes (TILs) and generating a favorable tumor microenvironment. Changes in IDO checkpoint inhibitor expression were also observed.

In the current studies, IMO-2125 (alone and in combination with an IDO-1 inhibitor) increased TIL infiltration and decreased the growth of treated and distant tumors, providing evidence of an enhanced systemic antitumor immune response compared to either agent given alone.

In the study we evaluated the antitumor activity of i.t. IMO-2125 in combination with an IDO1 inhibitor in a murine syngeneic colon carcinoma CT26 model.  There was a statistically significant decrease in the growth of both local and distant tumors which was greater for combination therapy than for either IMO-2125 or IDO-1 alone (for lung metastases: combination vs IMO-2125: P = 0.0393; combination vs IDO-1 inhibitor: P = 0.0128).

These results and previous observations with IMO plus anti-CTLA4 and IMO plus PD-1 demonstrate that combination immunotherapy with IMO-2125 has the potential to improve clinical outcomes over currently available anti-CTLA4 and PD-1 inhibitors, and now IDO-1 inhibitors.

In partnership with the MD Anderson Cancer Center, the company is currently conducting a Phase 1/2 clinical trial of intra-tumoral IMO-2125 in combination with ipilimumab (CTLA4) for the treatment of pembrolizumab (PD1) treated refractory metastatic melanoma patients. The study has also recently been amended to include an arm studying the combination of IMO-2125 and PD1 in the same patient population. (Original Source)

Shares of Idera Pharmaceuticals are currently trading at $1.91, up $0.01 or 0.68%. IDRA has a 1-year high of $4.42 and a 1-year low of $1.50. The stock’s 50-day moving average is $1.96 and its 200-day moving average is $2.58.

On the ratings front, Idera has been the subject of a number of recent research reports. In a report issued on March 10, Piper Jaffray analyst Edward Tenthoff maintained a Buy rating on IDRA, with a price target of $4, which implies an upside of 110.5% from current levels. Separately, on January 6, Wedbush’s Heather Behanna initiated coverage with a Buy rating on the stock and has a price target of $6.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Edward Tenthoff and Heather Behanna have a total average return of -3.4% and 11.2% respectively. Tenthoff has a success rate of 33.6% and is ranked #3362 out of 3807 analysts, while Behanna has a success rate of 50.0% and is ranked #648.